Table 2.
Matched cohort (n=121,050) | COVID-19 cohort (n=8,070) | |||
---|---|---|---|---|
Unadjusted | Model 1 | Model 2 | ||
Overall | Reference | 1.71 (1.20–2.37) | 1.69 (1.18–2.35) | 1.51 (1.05–2.10) |
Age group (yr) | ||||
< 60 | Reference | 2.29 (1.06–4.39) | 2.28 (1.05–4.36) | 2.10 (0.97–4.03) |
≥ 60 | Reference | 1.59 (1.05–2.30) | 1.59 (1.05–2.31) | 1.40 (0.93–2.05) |
Sex | ||||
Male | Reference | 1.72 (1.04–2.70) | 1.69 (1.02–2.66) | 1.39 (0.83–2.19) |
Female | Reference | 1.70 (1.01–2.69) | 1.69 (0.99–2.67) | 1.57 (0.93–2.50) |
Comorbidities | ||||
Without COPD | Reference | 1.91 (1.15–2.99) | 1.94 (1.16–3.04) | 1.91 (1.15–3.00) |
With COPD | Reference | 1.23 (0.73–1.96) | 1.24 (0.73–1.96) | 1.22 (0.72–1.94) |
Without asthma | Reference | 1.98 (1.25–2.99) | 2.00 (1.26–3.02) | 1.85 (1.16–2.80) |
With asthma | Reference | 1.30 (0.72–2.17) | 1.28 (0.71–2.14) | 1.15 (0.63–1.94) |
Values are presented as risk ratios (95% CI). Model 1: adjusted for type of insurance; Model 2: adjusted for type of insurance, asthma, and COPD. CI, confidence interval; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019.